Matsumura, Akane
Shigeta, Ayako
Kasai, Hajime
Yokota, Hajime
Terada, Jiro
Yamamoto, Keiko
Sugiura, Toshihiko
Matsumura, Takuma
Sakao, Seiichiro
Tanabe, Nobuhiro
Tatsumi, Koichiro
Funding for this research was provided by:
the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group, the Ministry of Health, Labor and Welfare
Pulmonary Hypertension Research Group from the Japan Agency for Medical Research and Development, AMED (17ek0109127h0003, 17ek0109127h0003, 17ek0109127h0003, 17ek0109127h0003)
Article History
Received: 2 February 2021
Accepted: 22 September 2021
First Online: 20 October 2021
Declarations
:
: The present study was a single-center retrospective investigation and was approved by the ethics committee of Chiba University (approved on June 1, 2009; approval number, 826). All patients provided informed consent.
: All study participants provided informed consent and the study design was approved by the appropriate ethics review board.
: NT received a research grant from Nippon Shinyaku and honoraria from Actelion Pharmaceuticals, Nippon Shinyaku, Pfizer, Bristol-Myers Squibb, and Bayer. NT, AS, and TJ belong to the endowed department sponsored by Actelion Pharmaceuticals. Other authors have declared that no competing interests exist.